1
|
Noori MS, Courreges MC, Bergmeier SC, McCall KD, Goetz DJ. Modulation of LPS-induced inflammatory cytokine production by a novel glycogen synthase kinase-3 inhibitor. Eur J Pharmacol 2020; 883:173340. [PMID: 32634441 PMCID: PMC7334664 DOI: 10.1016/j.ejphar.2020.173340] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Revised: 06/28/2020] [Accepted: 06/29/2020] [Indexed: 12/21/2022]
Abstract
Sepsis is a serious condition that can lead to long-term organ damage and death. At the molecular level, the hallmark of sepsis is the elevated expression of a multitude of potent cytokines, i.e. a cytokine storm. For sepsis involving gram-negative bacteria, macrophages recognize lipopolysaccharide (LPS) shed from the bacteria, activating Toll-like-receptor 4 (TLR4), and triggering a cytokine storm. Glycogen synthase kinase-3 (GSK-3) is a highly active kinase that has been implicated in LPS-induced cytokine production. Thus, compounds that inhibit GSK-3 could be potential therapeutics for sepsis. Our group has recently described a novel and highly selective inhibitor of GSK-3 termed COB-187. In the present study, using THP-1 macrophages, we evaluated the ability of COB-187 to attenuate LPS-induced cytokine production. We found that COB-187 significantly reduced, at the protein and mRNA levels, cytokines induced by LPS (e.g. IL-6, TNF-α, IL-1β, CXCL10, and IFN-β). Further, the data suggest that the inhibition could be due, at least in part, to COB-187 reducing NF-κB (p65/p50) DNA binding activity as well as reducing IRF-3 phosphorylation at Serine 396. Thus, COB-187 appears to be a potent inhibitor of the cytokine storm induced by LPS.
Collapse
Affiliation(s)
- Mahboubeh S Noori
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH, 45701, USA.
| | - Maria C Courreges
- Department of Specialty Medicine, Ohio University, Athens, OH, 45701, USA
| | - Stephen C Bergmeier
- Biomedical Engineering Program, Ohio University, Athens, OH, 45701, USA; Department of Chemistry and Biochemistry, Ohio University, Athens, OH, 45701, USA
| | - Kelly D McCall
- Department of Specialty Medicine, Ohio University, Athens, OH, 45701, USA; Biomedical Engineering Program, Ohio University, Athens, OH, 45701, USA; The Diabetes Institute, Ohio University, Athens, OH, 45701, USA; Molecular and Cellular Biology Program, Ohio University, Athens, OH, 45701, USA; Translational Biomedical Science Program, Ohio University, Athens, OH, 45701, USA
| | - Douglas J Goetz
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH, 45701, USA; Biomedical Engineering Program, Ohio University, Athens, OH, 45701, USA.
| |
Collapse
|
2
|
Noori MS, Bodle SJ, Showalter CA, Streator ES, Drozek DS, Burdick MM, Goetz DJ. Sticking to the Problem: Engineering Adhesion in Molecular Endoscopic Imaging. Cell Mol Bioeng 2020; 13:113-124. [PMID: 32175025 DOI: 10.1007/s12195-020-00609-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Accepted: 01/03/2020] [Indexed: 12/24/2022] Open
Abstract
Cancers of the digestive tract cause nearly one quarter of the cancer deaths worldwide, and nearly half of these are due to cancers of the esophagus and colon. Early detection of cancer significantly increases the rate of survival, and thus it is critical that cancer within these organs is detected early. In this regard, endoscopy is routinely used to screen for transforming/cancerous (i.e. dysplastic to fully cancerous) tissue. Numerous studies have revealed that the biochemistry of the luminal surface of such tissue within the colon and esophagus becomes altered throughout disease progression. Molecular endoscopic imaging (MEI), an emerging technology, seeks to exploit these changes for the early detection of cancer. The general approach for MEI is as follows: the luminal surface of an organ is exposed to molecular ligands, or particulate probes bearing a ligand, cognate to biochemistry unique to pre-cancerous/cancerous tissue. After a wash, the tissue is imaged to determine the presence of the probes. Detection of the probes post-washing suggests pathologic tissue. In the current review we provide a succinct, but extensive, review of ligands and target moieties that could be, or are currently being investigated, as possible cognate chemistries for MEI. This is followed by a review of the biophysics that determines, in large part, the success of a particular MEI design. The work draws an analogy between MEI and the well-advanced field of cell adhesion and provides a road map for engineering MEI to achieve assays that yield highly selective recognition of transforming/cancerous tissue in situ.
Collapse
Affiliation(s)
- Mahboubeh S Noori
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH 45701 USA
| | - Sarah J Bodle
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH 45701 USA.,Biomedical Engineering Program, Ohio University, Athens, OH 45701 USA
| | - Christian A Showalter
- Department of Biological Sciences, Ohio University, Athens, OH 45701 USA.,Molecular and Cellular Biology Program, Ohio University, Athens, OH 45701 USA
| | - Evan S Streator
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH 45701 USA
| | - David S Drozek
- Department of Specialty Medicine, Ohio University, Athens, OH 45701 USA
| | - Monica M Burdick
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH 45701 USA.,Biomedical Engineering Program, Ohio University, Athens, OH 45701 USA.,Molecular and Cellular Biology Program, Ohio University, Athens, OH 45701 USA.,Edison Biotechnology Institute, Ohio University, Athens, OH 45701 USA
| | - Douglas J Goetz
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH 45701 USA.,Biomedical Engineering Program, Ohio University, Athens, OH 45701 USA
| |
Collapse
|
3
|
Noori MS, Bhatt PM, Courreges MC, Ghazanfari D, Cuckler C, Orac CM, McMills MC, Schwartz FL, Deosarkar SP, Bergmeier SC, McCall KD, Goetz DJ. Identification of a novel selective and potent inhibitor of glycogen synthase kinase-3. Am J Physiol Cell Physiol 2019; 317:C1289-C1303. [PMID: 31553649 PMCID: PMC6962522 DOI: 10.1152/ajpcell.00061.2019] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Revised: 09/03/2019] [Accepted: 09/18/2019] [Indexed: 12/21/2022]
Abstract
Glycogen synthase kinase-3 (GSK-3) is a multitasking protein kinase that regulates numerous critical cellular functions. Not surprisingly, elevated GSK-3 activity has been implicated in a host of diseases including pathological inflammation, diabetes, cancer, arthritis, asthma, bipolar disorder, and Alzheimer's. Therefore, reagents that inhibit GSK-3 activity provide a means to investigate the role of GSK-3 in cellular physiology and pathophysiology and could become valuable therapeutics. Finding a potent inhibitor of GSK-3 that can selectively target this kinase, among over 500 protein kinases in the human genome, is a significant challenge. Thus there remains a critical need for the identification of selective inhibitors of GSK-3. In this work, we introduce a novel small organic compound, namely COB-187, which exhibits potent and highly selective inhibition of GSK-3. Specifically, this study 1) utilized a molecular screen of 414 kinase assays, representing 404 unique kinases, to reveal that COB-187 is a highly potent and selective inhibitor of GSK-3; 2) utilized a cellular assay to reveal that COB-187 decreases the phosphorylation of canonical GSK-3 substrates indicating that COB-187 inhibits cellular GSK-3 activity; and 3) reveals that a close isomer of COB-187 is also a selective and potent inhibitor of GSK-3. Taken together, these results demonstrate that we have discovered a region of chemical design space that contains novel GSK-3 inhibitors. These inhibitors will help to elucidate the intricate function of GSK-3 and can serve as a starting point for the development of potential therapeutics for diseases that involve aberrant GSK-3 activity.
Collapse
Affiliation(s)
- Mahboubeh S Noori
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, Ohio
| | - Pooja M Bhatt
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, Ohio
| | | | - Davoud Ghazanfari
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, Ohio
| | - Chaz Cuckler
- Biomedical Engineering Program, Ohio University, Athens, Ohio
| | - Crina M Orac
- Department of Chemistry and Biochemistry, Ohio University, Athens, Ohio
| | - Mark C McMills
- Department of Chemistry and Biochemistry, Ohio University, Athens, Ohio
| | - Frank L Schwartz
- Department of Specialty Medicine, Ohio University, Athens, Ohio
- The Diabetes Institute, Ohio University, Athens, Ohio
| | | | - Stephen C Bergmeier
- Biomedical Engineering Program, Ohio University, Athens, Ohio
- Department of Chemistry and Biochemistry, Ohio University, Athens, Ohio
| | - Kelly D McCall
- Department of Specialty Medicine, Ohio University, Athens, Ohio
- Biomedical Engineering Program, Ohio University, Athens, Ohio
- The Diabetes Institute, Ohio University, Athens, Ohio
| | - Douglas J Goetz
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, Ohio
- Biomedical Engineering Program, Ohio University, Athens, Ohio
| |
Collapse
|
4
|
Noori MS, Streator ES, Carlson GE, Drozek DS, Burdick MM, Goetz DJ. An adhesion based approach for the detection of esophageal cancer. Integr Biol (Camb) 2019; 10:747-757. [PMID: 30398503 DOI: 10.1039/c8ib00132d] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Esophageal cancer has a 5 year survival rate of ∼20%. This dismal prognosis is due, in part, to the fact that esophageal cancer often presents at a late stage. Thus, there is a critical need for assays that enable the early detection of cancerous tissue within the esophagus. The luminal surface of the esophagus expresses signature molecule(s) at sites of transformation providing an avenue for the development of in situ assays that detect neoplastic growth within the esophagus. An attractive approach, receiving increased attention, is the endoscopic administration of particles conjugated with ligands to signature molecules present on transforming tissue. Detection of the particles within the esophagus, post-washing, would indicate the presence of the signature molecule and thus transforming tissue. In this work, we utilized cancerous and normal esophageal cells to provide in vitro proof of principle for this approach utilizing ligand-conjugated microspheres and demonstrate the need, and provide the framework for, engineering this technology. Specifically, the study (i) reveals selective increased expression of signature molecules on cancerous esophageal cells relative to normal cells; (ii) demonstrates selective binding of ligand-conjugated microspheres to cancerous esophageal cells relative to normal cells; (iii) demonstrates that the selective recognition of cancerous, relative to normal esophageal cells, is highly dependent on the biophysical design of the assay; and (iv) advocates utilizing the knowledge from the field of cell adhesion as a guide for the effective development of ligand-conjugated particle-based schemes that seek to detect esophageal oncogenesis in situ.
Collapse
Affiliation(s)
- Mahboubeh S Noori
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, Ohio 45701, USA.
| | | | | | | | | | | |
Collapse
|
5
|
Allen AE, Noori MS, McCall KD, Bergmeier SC, Goetz DJ. Small Molecule Inhibition of IFN‐γ‐Induced Major Histocompatibility Complex Class II Expression by Thyroid Cells. FASEB J 2018. [DOI: 10.1096/fasebj.2018.32.1_supplement.842.9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Abigail E. Allen
- Chemical and Biomolecular EngineeringOhio UniversityAthensOH
- Biomedical Engineering ProgramOhio UniversityAthensOH
| | | | - Kelly D. McCall
- Biomedical Engineering ProgramOhio UniversityAthensOH
- Department of Specialty MedicineOhio UniversityAthensOH
- The Diabetes InstituteOhio UniversityAthensOH
| | - Stephen C. Bergmeier
- Biomedical Engineering ProgramOhio UniversityAthensOH
- Department of Chemistry and BiochemistryOhio UniversityAthensOH
| | - Douglas J. Goetz
- Chemical and Biomolecular EngineeringOhio UniversityAthensOH
- Biomedical Engineering ProgramOhio UniversityAthensOH
| |
Collapse
|
6
|
Noori MS, Courreges MC, Bergmeier SC, McCall KD, Goetz DJ. A Novel Potent and Selective Inhibitor of Glycogen Synthase Kinase‐3 (GSK‐3). FASEB J 2018. [DOI: 10.1096/fasebj.2018.32.1_supplement.842.8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Mahboubeh S. Noori
- Department of Chemical and Biomolecular EngineeringOhio UniversityAthensOH
| | | | - Stephen C. Bergmeier
- Biomedical Engineering ProgramOhio UniversityAthensOH
- Department of Chemistry and BiochemistryOhio UniversityAthensOH
| | - Kelly D. McCall
- Biomedical Engineering ProgramOhio UniversityAthensOH
- Department of Specialty MedicineOhio UniversityAthensOH
- The Diabetes InstituteOhio UniversityAthensOH
| | - Douglas J. Goetz
- Biomedical Engineering ProgramOhio UniversityAthensOH
- Department of Chemical and Biomolecular EngineeringOhio UniversityAthensOH
| |
Collapse
|
7
|
Noori MS, O'Brien JD, Champa ZJ, Deosarkar SP, Lanier OL, Qi C, Burdick MM, Schwartz FL, Bergmeier SC, McCall KD, Goetz DJ. Phenylmethimazole and a thiazole derivative of phenylmethimazole inhibit IL-6 expression by triple negative breast cancer cells. Eur J Pharmacol 2017; 803:130-137. [PMID: 28343970 DOI: 10.1016/j.ejphar.2017.03.049] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Revised: 03/17/2017] [Accepted: 03/22/2017] [Indexed: 01/11/2023]
Abstract
Inhibition of interleukin-6 (IL-6) holds significant promise as a therapeutic approach for triple negative breast cancer (TNBC). We previously reported that phenylmethimazole (C10) reduces IL-6 expression in several cancer cell lines. We have identified a more potent derivative of C10 termed COB-141. In the present work, we tested the hypothesis that C10 and COB-141 inhibit TNBC cell expressed IL-6 and investigated the potential for classical IL-6 pathway induced signaling within TNBC cells. A panel of TNBC cell lines (MDA-MB-231, Hs578T, MDA-MB-468) was used. Enzyme linked immunosorbent assays (ELISA) revealed that C10 and COB-141 inhibit MDA-MB-231 cell IL-6 secretion, with COB-141 being ~6.5 times more potent than C10. Therefore, the remainder of the study focused on COB-141 which inhibited IL-6 secretion, and was found, via quantitative real time polymerase chain reaction (QRT-PCR), to inhibit IL-6 mRNA in the TNBC panel. COB-141 had little, if any, effect on metabolic activity indicating that the IL-6 inhibition is not via a toxic effect. Flow cytometric analysis and QRT-PCR revealed that the TNBC cell lines do not express the IL-6 receptor (IL-6Rα). Trans-AM assays suggested that COB-141 exerts its inhibitory effect, at least in part, by reducing NF-κB (p65/p50) DNA binding. In summary, COB-141 is a potent inhibitor of TNBC cell expressed IL-6 and the inhibition does not appear to be due to non-specific toxicity. The TNBC cell lines do not have an intact classical IL-6 signaling pathway. COB-141's inhibitory effect may be due, at least in part, to reducing NF-κB (p65/p50) DNA binding.
Collapse
Affiliation(s)
- Mahboubeh S Noori
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH 45701, USA
| | - John D O'Brien
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH 45701, USA; Biomedical Engineering Program, Ohio University, Athens, OH 45701, USA
| | - Zachary J Champa
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH 45701, USA; Biomedical Engineering Program, Ohio University, Athens, OH 45701, USA
| | | | - Olivia L Lanier
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH 45701, USA
| | - Chunyan Qi
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH 45701, USA; Biomedical Engineering Program, Ohio University, Athens, OH 45701, USA
| | - Monica M Burdick
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH 45701, USA; Biomedical Engineering Program, Ohio University, Athens, OH 45701, USA
| | - Frank L Schwartz
- Department of Specialty Medicine, Ohio University, Athens, OH 45701, USA; The Diabetes Institute, Ohio University, Athens, OH 45701, USA
| | - Stephen C Bergmeier
- Biomedical Engineering Program, Ohio University, Athens, OH 45701, USA; Department of Chemistry and Biochemistry, Ohio University, Athens, OH 45701, USA
| | - Kelly D McCall
- Biomedical Engineering Program, Ohio University, Athens, OH 45701, USA; Department of Specialty Medicine, Ohio University, Athens, OH 45701, USA; The Diabetes Institute, Ohio University, Athens, OH 45701, USA
| | - Douglas J Goetz
- Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH 45701, USA; Biomedical Engineering Program, Ohio University, Athens, OH 45701, USA
| |
Collapse
|
8
|
Noori MS, Bodle SJ, Carlson GE, Drozek DS, Burdick MM, Goetz DJ. Abstract 3991: Differentiating esophageal cancer cells from normal cells using ligand-conjugated microspheres. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-3991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cancer of the esophagus has a dismal overall prognosis and low 5 year survival rate due to its aggressive nature and the fact that it often presents at a late stage. Biochemical changes present on transforming tissue provide an opportunity for the early detection of cancer within the esophagus and thus the promise of a more favorable prognosis and a higher survival rate. Recently, there has been an increasing effort to detect cancer of the esophagus by introducing, during an endoscopic procedure, soluble molecules (ligands) cognate to moieties preferentially expressed on transforming tissue. The success of this approach depends on the selective binding of the ligand to transforming tissue relative to normal tissue. For soluble ligands, the factors that dictate the selective binding depend on a very small number of factors. In contrast, if the ligands are conjugated to particles, there are a large number of controllable factors that can be manipulated to “engineer” the detection scheme and thus optimize selective recognition of transforming tissue.
In this study, we utilized an in vitro system to investigate the feasibility of the ligand-conjugated particle approach. First, we explored the surface chemistry of an esophageal adenocarcinoma cell line, OE19, relative to a normal esophageal cell line, HEEpiC, using flow cytometric analysis. Among other differences, we found that the OE19 cell line expresses relatively high levels of the tetrasaccharides sialyl Lewis A (sLea) and sialyl Lewis X (sLex). sLea and sLex are known cognate molecules for the selectin family of adhesion molecules, in particular E-selectin. Thus, we conjugated an E-selectin construct to 10 μm diameter microspheres. The E-selectin construct consisted of the extracellular domain of E-selectin fused to the Fc domain of IgG. Flow cytometric analysis revealed that the E-selectin construct was conjugated to the microspheres and that the E-selectin portion of the molecule was available for binding. To roughly simulate the introduction of the conjugated microspheres during an endoscopic procedure, a parallel plate flow chamber was used. A planar substrate of either OE19 or HEEpiC cells was placed in the flow chamber and a suspension of E-selectin or IgG (negative control) microspheres were perfused through the flow chamber. We observed that the E-selectin microspheres exhibited significantly greater adhesion to the OE19 cells relative to the HEEpiC cells. In contrast, IgG microspheres exhibited negligible adhesion to the OE19 and HEEpiC cells. Combined, this study provides proof of concept for an assay approach that could be engineered to detect transforming tissue present within the esophagus.
Citation Format: Mahboubeh S. Noori, Sarah J. Bodle, Grady E. Carlson, David S. Drozek, Monica M. Burdick, Douglas J. Goetz. Differentiating esophageal cancer cells from normal cells using ligand-conjugated microspheres. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3991.
Collapse
|
9
|
Abstract
Improvement of enzymatic hydrolysis and ethanol production from softwood pine was conducted by pretreatment with 8% (w/v) NaOH at different temperatures of 0, 25, and 80 °C for 2 h.
Collapse
Affiliation(s)
- Mahboubeh S. Noori
- Department of Chemical Engineering
- Isfahan University of Technology
- Isfahan 84156-83111
- Iran
- Chemical and Biomolecular Engineering Department
| | - Keikhosro Karimi
- Department of Chemical Engineering
- Isfahan University of Technology
- Isfahan 84156-83111
- Iran
- Industrial Biotechnology Group
| |
Collapse
|